Furthermore, similar beneficial effects were observed in a second AD mouse model, the 15 months old 3xTg‐AD mice, including increased Aβ plaque clearance (Figure S9A, Supporting Information), decreased soluble Aβ1–40 and Aβ1–42 levels in the hippocampus and cortex (Figure S9B,C, Supporting Information), and reduced tau phosphorylation, as confirmed by immunohistochemistry (Figure S9D, Supporting Information) and Western blot analyses (Figure S9E,F, Supporting Information). Here, MAPT is linked to Alzheimer disease.